GLPwatch

A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

NCT07754461 · Recruiting

Last updated 2026-08-27

This clinical trial is testing whether the medication survodutide helps people with type 2 diabetes better control their blood sugar levels.

Status Recruiting Currently enrolling participants.
Phase Phase 3 Confirms effectiveness in a large group before approval.
Type Interventional (clinical trial)
Design Randomized, quadruple-blind treatment study
Participants 600 people Planned (estimated).
Who can join Ages 18+ · all sexes
Timeline Started 2026-08 · est. completion 2028-05
Where 120 sites · Australia, Canada, India, New Zealand, Puerto Rico, United States

What this study is testing ClinicalTrials.gov NCT07754461 ↗

Description as written by the study sponsor.

This study aims to find out whether a study medicine called survodutide helps people control their blood sugar. Adults who live with type 2 diabetes and with a body mass index (BMI) of 23 kg/m2 or higher can join. The study has 3 parts. In each part the study compares survodutide with placebo. Survodutide is being developed to treat several health problems including type 2 diabetes. Placebo looks like survodutide but does not contain any medicine. Depending on a person's diabetes treatment, a person will be assigned either to * Part A: healthy eating and physical activity * Part B: diabetes tablets (no injection of insulin) * Part C: injection of insulin (with or without diabetes tablets) Participants are randomly put into 1 of 3 groups, which means the group is chosen by chance. Two groups of participants get survodutide at different dose levels, and the third group gets placebo as injection under the skin once a week. You have a 2 in 3 chance of getting survodutide. During the study, participants continue their regular diabetes treatment. Participants are in the study for about 1 year and 2 months. During this time, they attend up to 12 visits at the site and receive at least 9 phone calls. Study doctors regularly test participants' blood sugar by checking their HbA1c values and other laboratory test results. The study doctor also regularly checks participants' health and takes note of any changes. For each study part, the results will be compared between the survodutide and the placebo group to see whether the treatment works.

Treatments tested

Main thing measuredAbsolute change in glycosylated haemoglobin A1c (HbA1c) (%) from baseline to Week 41
SponsorBoehringer Ingelheim
Conditions studiedType 2 Diabetes
GLP-1 drugs survodutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07754461 ↗